Business Context and Reporting Period
This Form 8-K was filed by Landec Corporation (not Lifecore Biomedical, Inc.) on June 2, 2022. The report discloses a material event under Regulation FD regarding the divestiture of a specific business segment.
Key Financial Metrics
- Transaction Proceeds: $3.2 million in cash received from the sale of the BreatheWay technology business.
- Revenue/Profit/Cash Flow: The filing text does not provide clear values for overall revenue, net income, operating cash flow, or margins for the period.
- Debt and Liquidity: The filing text does not provide clear values for total debt or liquidity ratios.
Material Changes
The primary material change is the completion of the sale of the Company's BreatheWay technology business. This transaction resulted in an immediate cash inflow of $3.2 million and the removal of the associated assets and operations from the Company's portfolio.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, forward-looking outlook statements, or specific risk factors beyond the standard disclosure that the press release information is not deemed "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Verify the exact terms of the BreatheWay technology business sale agreement.
- Confirm the impact of the $3.2 million cash proceeds on the Company's balance sheet in the next quarterly report.
- Review the press release (Exhibit 99.1) for details on the buyer and any ongoing obligations.
- Check subsequent filings for the accounting treatment of the divestiture (e.g., gain/loss on sale).